DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceuticals products based on its proprietary drug formulations and delivery platform technologies in the United States, Europe, Japan, and internationally. The company was founded in 1998 and is based in Cupertino, California.
DRRX Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Durect Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Durect Corp ranked in the 58th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. In terms of the factors that were most noteworthy in this DCF analysis for DRRX, they are:
The company has produced more trailing twelve month cash flow than merely 9.1% of its sector Healthcare.
Durect Corp's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.
Durect Corp's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -8.5. This coverage rate is greater than that of merely 9% of stocks we're observing for the purpose of forecasting via discounted cash flows.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as DRRX, try UTHR, MEDP, HNGR, QDEL, and UNH.
DURECT Corporation (Nasdaq: DRRX) today announced it has initiated recruiting patients for its randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the safety and efficacy of DUR-928 in hospitalized COVID-19 infected patients with acute liver or kidney injury. The primary efficacy endpoint is a composite of survival and being free of acute organ failure at Day 28. The trial will enroll approximately 80 patients.
DURECT Corporation (Nasdaq: DRRX) today announced that it is set to join the broad-market Russell 3000® Index as a result of the 2020 Russell indexes annual reconstitution, effective after the US stock market opens today, June 29, 2020.
DURECT announces Gilead Sciences will terminate the License Agreement in July 2019, effective December 22, for the development and commercialization of a long-acting injectable HIV investigational product utilizing DURECT's SABER technology.DURECT anticipates recognizing remaining deferred revenue of ~$23.1M Q2 of 2020, associated with the receipt of the upfront license and development milestone payment.(DRRX) is...